Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | GABRP | O00591 | 2/20 | 0.44 |
| ▸ | GABRD | O14764 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.44 |
| ▸ | GABRE | P78334 | 2/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29118324 | 0.98 | KEAP1 (0.48) | KEAP1DCLRE1BCES2CES1GABRP | |
| SCHEMBL15053053 | 0.87 | LMNA (0.47) | KEAP1DCLRE1BCES2CES1GABRP | |
| SCHEMBL5188661 | 0.86 | CES2 (0.47) | KEAP1CES2CES1KDM4EMAPT | |
| SCHEMBL16429122 | 0.86 | KEAP1 (0.52) | KEAP1DCLRE1BCES2CES1KDM4E | |
| SCHEMBL9518777 | 0.85 | DCLRE1B (0.55) | DCLRE1BKDM4EMAPTLMNAHSD17B10 | |
| SCHEMBL5447109 | 0.85 | CES2 (0.47) | KEAP1DCLRE1BCES2CES1GABRP | |
| SCHEMBL365167 | 0.84 | KEAP1 (0.50) | KEAP1DCLRE1BCES2CES1KDM4E | |
| SCHEMBL8576783 | 0.84 | KEAP1 (0.55) | KEAP1DCLRE1BCES2CES1GABRP | |
| SCHEMBL19695738 | 0.82 | MAPK8 (0.44) | KEAP1CES2CES1KDM4EMAPT | |
| SCHEMBL21815740 | 0.82 | KEAP1 (0.48) | KEAP1DCLRE1BCES2CES1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516479-B1 | NEW INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS | BASF CORP (US) | 2016-04-20 | — | — | EP | claimed |
| US-8211819-B2 | Internal and external donor compounds for olefin polymerization catalysts | BASF CORPORATION (US) | 2012-07-03 | — | — | US | claimed |
| EP-2361906-A1 | Process for preparing rosuvastatin | AstraZeneca UK Limited (GB) | 2011-08-31 | — | — | EP | claimed |
| US-20110152481-A1 | Internal and external donor compounds for olefin polymerization catalysts | BASF CATALYSTS LLC (US) | 2011-06-23 | — | — | US | claimed |
| US-20080207903-A1 | Chemical Process | ASTRAZENECA UK LIMITED (GB) | 2008-08-28 | — | — | US | claimed |
| EP-1871747-A2 | PROCESS FOR PREPARING ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2008-01-02 | — | — | EP | claimed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | claimed |
| EP-0069598-B1 | PREPARATION OF AROMATIC KETONES | RAYCHEM CORPORATION (a California corporation) (US) | 1984-12-19 | — | — | EP | claimed |
| EP-4660182-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING ARYL PYRIDINE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025202185-A1 | PROCESS FOR THE FUNCTIONALIZATION OF AN AROMATIC OR HETEROAROMATIC AMINO COMPOUND | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-10-02 | — | — | WO | disclosed |
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA | 2025-04-24 | — | — | US | disclosed |
| CN-118201920-A | PAPD5 inhibitors and methods of use thereof | 儿童医疗中心公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023081452-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-3763367-A1 | PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| US-4910206-A | Endotoxin induced lung injury | SANDOZ PHARMACEUTICALS CORP. (US) | 1990-03-20 | — | — | US | disclosed |
| WO-1988006157-A1 | 5-HETERO- OR ARYL-SUBSTITUTED-IMIDAZO[2,1-a]ISOQUINOLINES | SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. (AT) | 1988-08-25 | — | — | WO | disclosed |
| EP-0258175-A2 | 5-hetero- or aryl-substituted-imidazo[2,1-a]isoquinolines | SANDOZ AG (CH) | 1988-03-02 | — | — | EP | disclosed |
| US-4140859-A | Dilithiated 2-(o-tolyl)-2-imidazolines | SANDOZ, INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4101553-A | Imidazo[2,1-a]isoquinolines | SANDOZ, INC. (US) | 1978-07-18 | — | — | US | disclosed |
| US-3932450-A | Intermediates in the preparation of imidazo(2,1-alpha)isoindoles | SANDOZ, INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | CDK8, CDK9, CDK18 | KEAP1 2353/4885DCLRE1B 131/4885CES2 3974/4885 |
| US-20080207903-A1 | Chemical Process | CYP2C9, CYP2B6, CYP7A1 | KEAP1 458/4885DCLRE1B 2724/4885CES2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.